Featured
A research team from CHOP and the Perelman School of Medicine at the University of Pennsylvania, supported by the National Institutes of Health, developed a customized gene therapy by utilizing the gene editing platform CRISPR.
Clinical trial for stage 3 colon cancer shows promise.